A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Trial status:Recruitment Complete
Trial ID:
GO39733
NCT ID:
NCT03289962
EudraCT ID:
2017-001475-23
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Recruitment Complete

Trial Details

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).

Medical Condition
  • Skin Cancer
  • Lung Cancer
  • Bladder Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Kidney Cancer
  • Head and Neck Cancer
  • Solid Tumors
    • Trial Drug
  • Autogene cevumeran
    • See more
  • Atezolizumab
    • Phase
    Phase 1
    Type
    Interventional
    Estimated Enrolment
    272
    Estimated Trial Date
    Dec 2017 - Mar 2025

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    HonorHealth Research Institute ? Bisgrove
    Scottsdale, Arizona, United States, 85258
    Status
    Location
    The Los Angeles Clinic
    Los Angeles, California, United States, 90025
    Status
    Location
    UCSF Comprehensive Cancer Ctr
    San Francisco, California, United States, 94143
    Status
    Location
    Stanford Cancer Center
    Stanford, California, United States, 94305
    Status
    Location
    University of Colorado
    Aurora, Colorado, United States, 80045-2517
    Status
    Location
    Yale University Cancer Center, Smilow Cancer Hospital
    New Haven, Connecticut, United States, 06511
    Status